DCTPepD_ID,ClinicalTrials.gov_Identifier,Title,Condition_or_disease,Phase,Purpose
DCTPepD0001,NCT01020448,"Prostate Cancer Antigen-3 (PCA-3) and TMPRSS2-ERG (T2-ERG) Score Changes During Initiation of Androgen Deprivation Therapy (ADT) With Triptorelin 22.5mg in Patients With Advanced Prostate Cancer (PCA): A Phase III, Single Arm Multicentre Study",Prostate Cancer,Phase 3,Treatment
DCTPepD0001,NCT01753297,"A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients",Prostate Cancer,Phase 4,Treatment
DCTPepD0001,NCT01969578,"A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)",Salivary Gland Cancer,Phase 2,Treatment
DCTPepD0001,NCT00667069,"Randomized, Multicenter Study Comparing the Immediate Adjuvant Radiotherapy Associate With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) vs Delayed Radiotherapy Until Biochemical Relapse Associated With Hormonal Therapy of LH-RH Analogue (Decapeptyl® LP) in Patients With Operable Prostate Cancer pT3 R1 pN0 or pNx at Intermediate Risk.",Prostate Cancer,Phase 3,Treatment
DCTPepD0001,NCT00412022,"Phase III Randomized Study of the Effects on Bone Mineral Density of Tamoxifen, Letrozole, and Letrozole + Zoledronic Acid as Adjuvant Treatment of Patients With Early Breast Cancer; VERSION 2 AMENDED Phase 3 Study of Triptorelin and Tamoxifen, Letrozole, or Letrozole + Zoledronic Acid in Adjuvant Treatment of Premenopausal Endocrine Responsive Breast Cancer Patients.",Breast Cancer,Phase 3,Treatment
DCTPepD0002,NCT03936218,"A Two Arm, Multi Centric, Randomised, Open Label, Parallel Study to Compare Pharmacodynamics of Subcutaneous Goserelin 10.8mg Injection (Sponsor) With ZOLADEX® 10.8mg Injection (AstraZeneca) in Patients With Advanced Prostate Cancer",Advanced Prostate Cancer,Phase 3,Treatment
DCTPepD0002,NCT00186121,"A Phase II Trial of Arimidex Plus Zoladex in the Treatment of Hormone Receptor Positive, Metastatic Carcinoma of the Breast in Premenopausal Women",Breast Cancer,Phase 2,Treatment
DCTPepD0002,NCT01073865,"An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer.",Breast Cancer,Phase 3,Treatment
DCTPepD0002,NCT02586675,The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer,Breast Cancer; Breast Cancer - Female; Breast Cancer - Male,Phase 1,Treatment
DCTPepD0002,NCT02430480,Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer,Prostate Cancer,Phase 2,Treatment
DCTPepD0003,NCT03289741,"A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine Tumors",Neuroendocrine Tumors,Phase 4,Treatment
DCTPepD0003,NCT02409849,Randomized Phase II Study of Octreotide LAR as Maintenance Treatment After First-line Chemotherapy for Patients With Unresectable or Metastatic Gastro-entero-pancreatic or Esophageal Neuroendocrine Carcinomas,Gastro-entero-pancreatic Carcinoma; Esophageal Neuroendocrine Carcinoma,Phase 2,Treatment
DCTPepD0003,NCT05459844,"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With Inoperable, Progressive, , Well Differentiated， Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumours",Neuroendocrine Tumors,Phase 3,Treatment
DCTPepD0003,NCT01578239,"A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours",Carcinoid Tumor of the Small Bowel; Neuroendocrine Tumour,Phase 3,Treatment
DCTPepD0003,NCT00427349,A Phase II Clinical and Biologic Study of AMG 706 and Octreotide in Patients With Low-Grade Neuroendocrine Tumors,Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Neoplastic Syndrome,Phase 2,Treatment
DCTPepD0004,NCT01862003,"AZD8931, an Inhibitor of EGFR, ERBB2 and ERBB3 Signalling, in Combination With FOLFIRI: a Phase I/II Study to Determine the Importance of Schedule and Activity in Colorectal Cancer",Metastatic Colorectal Cancer; Recurrent Colorectal Cancer,Phase 2,Treatment
DCTPepD0004,NCT01596530,A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients With Early Breast Cancer Who Are Ineligible for Treatment With Trastuzumab as Defined by IHC Status,Breast Neoplasm,Phase 1,Treatment
DCTPepD0004,NCT01003158,"A Phase I, Open-label, Multiple-dose, Dose-escalation Study To Assess the Safety and Tolerability of AZD8931 Monotherapy in Japanese Patients With Advanced Solid Malignancies and in Combination With Paclitaxel in Japanese Female Patients With Advanced Breast Cancer",Neoplasms; Metastatic Cancer; Breast Cancer,Phase 1,Treatment
DCTPepD0004,NCT00900627,"A Phase I/II Multi-centre Study of AZD8931 in Combination With Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumours and in a Selected Population With Low HER2-expressing Locally Recurrent and/or Metastatic Breast Cancer",Neoplasms; Breast Neoplasms; Breast Cancer,Phase 1/2,Treatment
DCTPepD0004,NCT00637039,"A Phase 1, Open-label, Multiple-dose, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8931 in Patients With Advanced Solid Malignancies",Advanced Solid Malignancies,Phase 1,Treatment
DCTPepD0005,NCT03946527,Exploratory Phase II Study of LAnreotide in Metastatic Pheochromocytoma/PARAganglioma (LAMPARA),Paraganglioma; Pheochromocytoma,Phase 2,Treatment
DCTPepD0005,NCT04427787,A Phase II Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in Gastroenteropancreatic (GEP) and Thoracic Neuroendocrine Tumor (NET): The LOLA Trial,Metastatic Well Differentiated Neuroendocrine Neoplasm; Neuroendocrine Tumors,Phase 2,Treatment
DCTPepD0005,NCT02651987,"Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days",Pancreatic Tumours; Midgut Neuroendocrine Tumours,Phase 2,Treatment
DCTPepD0005,NCT03043664,Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors,Gastroenteropancreatic Neuroendocrine Tumors,Phase 1/2,Treatment
DCTPepD0005,NCT00842348,Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour,Non Functioning Entero-pancreatic Endocrine Tumour,Phase 3,Treatment
DCTPepD0006,NCT00841113,"Phase III Study of the Comparison of Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer. A One Year Randomised, Open Label, Multi-Centre Phase III Trial.",Prostate Cancer,Phase 3,Treatment
DCTPepD0006,NCT00100243,Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy,Prostate Cancer,Phase 2,Treatment
DCTPepD0006,NCT00103623,Incidence of Immediate Onset Systemic Allergic Reactions in Patients Treated With Plenaxis®,Prostate Cancer,Phase 4,Treatment
DCTPepD0007,NCT03069937,A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma.,Metastatic Prostatic Adenocarcinoma,Phase 2,Treatment
DCTPepD0007,NCT02475057,"A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists",Prostatic Neoplasms; Cardiovascular Diseases,Phase 4,Treatment
DCTPepD0007,NCT01512472,"Randomized, Multicentre Efficacy and Safety Study Comparing 10 Mons vs 4 Mons Degarelix Therapy in Prolonging the Off Treatment Interval in Men With Localized Prostate Cancer Receiving Intermittent ADT for Biochemical Recurrence Following Radical Local Therapy",Prostate Cancer Recurrent,Phase 4,Treatment
DCTPepD0007,NCT02015871,"An Extension Long-Term Safety and Tolerability Trial of Degarelix, Following a 1-year Open-Label, Multi-Centre, Randomised, Parallel-group Trial in Which the Efficacy and Safety of Degarelix One-month Dosing Regimen Was Compared With Goserelin in Chinese Patients With Prostate Cancer Requiring Androgen Ablation Therapy",Prostate Cancer,Phase 3,Treatment
DCTPepD0007,NCT01994239,A Multicenter Randomised Phase II Study Comparing the Efficiency of a HT Concomitant With RT vs RT Alone in the Salvage of Patients With a Detectable PSA After Prostatectomy,Adenocarcinoma of Prostate,Phase 2,Treatment
DCTPepD0008,NCT01053390,A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma,Gallbladder Neoplasms,Phase 3,Treatment
DCTPepD0008,NCT02631616,Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET,Prostatic Neoplasms,Phase 1,Treatment
DCTPepD0008,NCT01914692,Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection -a Prospective Randomized Controlled Study,Gastric Cancer After D2 Lymph Node Dissection,Phase 4,Treatment
DCTPepD0008,NCT01053390,A Phase III Study of New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma,Gallbladder Neoplasms,Phase 3,Treatment
DCTPepD0008,NCT03000946,"Prevention of Postoperative Pancreatic Fistula by SOMATOSTATIN Compared to OCTREOTIDE: Prospective, Randomized, Controlled Study",Pancreatic Surgery,Phase 3,Prevention
DCTPepD0009,NCT00054106,A Phase I Study Of Combination Neoadjuvant Hormone Therapy And Weekly OGX-011 (Clusterin Antisense Oligonucleotide) Prior To Radical Prostatectomy In Patients With Localized Prostate Cancer,Prostate Cancer,Phase 1,Treatment
DCTPepD0009,NCT00002633,"Phase III Randomized Trial Comparing Total Androgen Blockade Versus Total Androgen Blockade Plus Pelvic Irradiation in Clinical Stage T3-4, N0, M0 Adenocarcinoma of the Prostate",Prostate Cancer,Phase 3,Treatment
DCTPepD0009,NCT01546987,Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) With a GNRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT With a GNRH Agonist and TAK-700 For Men With High Risk Prostate Cancer,Prostate Cancer,Phase 3,Treatment
DCTPepD0009,NCT05050084,Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE),Prostate Adenocarcinoma,Phase 3,Treatment
DCTPepD0009,NCT00627406,A Prospective Randomised Study to Evaluate the Effect of Triggering Ovulation With GnRHa (Buserelin) and Low Dose hCG (Pregnyl) as Compared to the Use of Conventional Doses of hCG (Pregnyl),OHSS (Ovarian Hyperstimulation),Phase 4,Treatment
DCTPepD0010,NCT02854072,"A Prospective, Randomized, Open-label, Multicenter, Parallel Design, Phase III Study to Assess the Efficacy and Safety of GV1001 Concurrent With Gemcitabine/Capecitabine Versus Gemcitabine/Capecitabine Alone in Treating Locally Advanced and Metastatic Pancreatic Cancer Patients",Pancreatic Cancer,Phase 3,Treatment
DCTPepD0010,NCT00444782,"""Heptovax"" - A Phase II, Open-Label Trial Evaluating the Safety and Efficacy of GV1001 in Advanced Hepatocellular Carcinoma.","Carcinoma, Hepatocellular",Phase 2,Treatment
DCTPepD0010,NCT01247623,Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma,Malignant Melanoma,Phase 1/2,Treatment
DCTPepD0010,NCT04032067,"A Randomized, Active-Controlled, Double-Blind, Parallel Design, Multi-Center, Phase III Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)",Benign Prostatic Hyperplasia (BPH),Phase 3,Treatment
DCTPepD0010,NCT03184467,"A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients",Alzheimer Disease,Phase 2,Treatment
DCTPepD0011,NCT03643133,"Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response)",Osteosarcoma,Phase 2,Treatment
DCTPepD0011,NCT00631631,Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE) for High-risk Osteosarcoma,Osteosarcoma,,Treatment
DCTPepD0011,NCT02441309,A Mechanistic Study Of Mifamurtide (MTP-PE) In Patients With Metastatic And/Or Recurrent Osteosarcoma,Osteosarcoma,Phase 2,Treatment
DCTPepD0011,NCT01459484,ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2),Osteosarcoma,Phase 2,Treatment
DCTPepD0011,NCT04062721,Feasibility and Safety of Local Immunomodulation Combined With Radiofrequency Ablation for Unresectable Colorectal Liver Metastases: A Monocentric Phase I Trial,Unresectable Colorectal Liver Metastases,Phase 1,Treatment
DCTPepD0012,NCT01775553,Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib,Relapse Multiple Myeloma; Refractory Multiple Myeloma,Phase 2,Treatment
DCTPepD0012,NCT02257476,A Phase I Study of Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Malignancies,Neoplasms; Malignancies,Phase 1,Treatment
DCTPepD0012,NCT02145403,Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and Graft-versus-host Disease in Allogeneic Hematopoietic Cell Transplantation for High-risk Hematologic Malignancies,"Hematologic Malignancies
; Relapse; Graft-Versus-HostDisease",Phase 1/2,Treatment
DCTPepD0012,NCT02142530,Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study,Non-Hodgkin Lymphoma; Diffuse Large B-cell Lymphoma; Mantle Cell Lymphoma; Follicular Lymphoma; Peripheral T-cell Lymphoma,Phase 1,Treatment
DCTPepD0012,NCT01926665,"Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Patients With Mantle Cell (MCL), T-cell (TCL), and Diffuse B-Cell Lymphoma (DLBCL)",Lymphoma,Phase 1,Treatment
DCTPepD0013,NCT03972488,"A Phase III Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",Gastro-enteropancreatic Neuroendocrine Tumor,Phase 3,Treatment
DCTPepD0013,NCT01456078,A Multicenter Phase II-Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors,Neuroendocrine Tumors; Liver Metastases,Phase 2,Treatment
DCTPepD0013,NCT03325816,Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer,Small Cell Lung Cancer; Small Cell Lung Cancer Extensive Stage,Phase 1/2,Treatment
DCTPepD0013,NCT04750954,A Phase 1b Trial of M3814 (Peposertib) in Combination With Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs),Neuroendocrine Neoplasm,Phase 1,Treatment
DCTPepD0013,NCT03971461,"A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma",Meningioma,Phase 2,Treatment
DCTPepD0014,NCT00198263,An Open-Label Study Using the Medpulser® Electroporation System to Treat Head and Neck Cancer,Head and Neck Cancer,Phase 4,Treatment
DCTPepD0014,NCT03225781,A Clinical Trial Using Electrochemotherapy With Bleomycin for the Treatment of Non-metastatic Unresectable Pancreatic Cancer,Pancreatic Cancer,Not Applicable,Treatment
DCTPepD0014,NCT03628417,"Fázis II, randomizált, kettős Vak vizsgálat a bőr metasztázisok kezelésére kálcium elektroporációval",Cutaneous Melanoma,Not Applicable,Treatment
DCTPepD0014,NCT01872923,"Dose Escalating Study to Evaluate the Tolerability, Efficacy and Safety of Amphinex 0.125 mg/kg or Lower in Amphinex-based PCI of Bleomycin in Patients With Local Recurrence or Advanced/Metastatic, Cutaneous or Sub-cutaneous Malignancies.",Cutaneous or Sub-cutaneous Malignancies,Phase 1,Treatment
DCTPepD0014,NCT05395962,Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer: the ElechtraPlatinum Study. A Randomized Controlled Trial,Vulvar Cancer,Phase 2,Treatment
DCTPepD0015,NCT01741155,A 2-Part Phase 2 Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy,Non Small Cell Lung Cancer (NSCLC),Phase 2,Treatment
DCTPepD0015,NCT01773785,Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line Treatment for Patients With Advanced Biliary Cancer,Biliary Cancer,Phase 2,Treatment
DCTPepD0015,NCT00613691,"A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma",Carcinoma,Phase 1,Treatment
DCTPepD0016,NCT03059147,"A Phase I Study of SF1126, a Dual PI3 Kinase and Bromodomain Inhibitor, in Combination With Nivolumab in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A-B7 Cirrhosis",Advanced Hepatocellular Carcinoma,Phase 1,Treatment
DCTPepD0016,NCT02337309,Phase I Study of SF1126 for Patients With Relapsed or Refractory Neuroblastoma,Neuroblastoma,Phase 1,Treatment
DCTPepD0016,NCT02644122,"A Phase II Open Label Study of the PI3 Kinase (PI-3) Inhibitor, SF1126, in Patients With Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes",Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma,Phase 2,Treatment
DCTPepD0016,NCT00907205,"A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors",Advanced or Metastatic Solid Tumors; Cancer; Solid Cancers,Phase 1,Treatment
DCTPepD0017,NCT03129828,"Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the Treatment of Elderly Patients (Age 61-80 Years) With CD20+ Diffuse Large B-cell Lymphoma, IPI ≥ 2",Diffuse Large B Cell Lymphoma,Phase 1/2,Treatment
DCTPepD0017,NCT02356458,Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.,Mantle Cell Lymphoma,Phase 1/2,Treatment
DCTPepD0017,NCT02613598,Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma,"Hodgkin's Lymphoma; Lymphoma, Non-Hodgkin",Phase 1,Treatment
DCTPepD0017,NCT01736943,Phase II Trial of the Combination of Subcutaneous (SQ) Bortezomib and Pegylated Liposomal Doxorubicin (PLD or Doxil or LipoDox) for the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML),Acute Myelogenous Leukemia,Phase 2,Treatment
DCTPepD0017,NCT03345303,Bortezomib in Treating Patients With Intrahepatic Cholangiocellular Carcinoma Featuring PTEN Deficiency,Intrahepatic Cholangiocarcinoma,Phase 3,Treatment
DCTPepD0018,NCT01394263,"Phase III, Open-Label Randomized, Parallel, Active-Control Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Metastatic Prostate Cancer",Prostate Cancer; Adenocarcinoma of the Prostate,Phase 3,Treatment
DCTPepD0018,NCT01574846,"Prospective, Multicentre, Non-interventional (Observational) Study of VANTAS® for the Treatment of Patients With Advanced Prostate Cancer.",Prostate Cancer,,Treatment
DCTPepD0018,NCT04513717,Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*),Metastatic Malignant Neoplasm in the Bone; Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IIIA Prostate Cancer AJCC v8; Stage IIIB Prostate Cancer AJCC v8; Stage IIIC Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8,Phase 3,Treatment
DCTPepD0018,NCT05050084,Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE),Prostate Adenocarcinoma,Phase 3,Treatment
DCTPepD0018,NCT00779103,"Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Children With Central Precocious Puberty",Central Precocious Puberty,Phase 3,Treatment
DCTPepD0019,NCT03035032,A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT),Prostate Cancer,Phase 4,Treatment
DCTPepD0019,NCT02319837,"A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy",Hormone Sensitive Prostate Cancer; Prostate Cancer; Cancer of the Prostate,Phase 3,Treatment
DCTPepD0019,NCT02508636,Phase II Trial of Definitive Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer,Prostatic Neoplasms; Pelvic Nodal,Phase 2,Treatment
DCTPepD0019,NCT00254397,Study of the Modulatory Activity of an LHRH-Agonist (Leuprolide) on Melanoma Peptide Vaccines as Adjuvant Therapy in Melanoma Patients,Melanoma,Phase 2,Treatment
DCTPepD0019,NCT00903162,Extended Endocrine Therapy for Premenopausal Women With Breast Cancer,Breast Cancer,Phase 2,Treatment
DCTPepD0020,NCT03903419,Feasibility Study for the Realization of 68Ga-PSMA PET-CT and 18F-FDOPA PET-CT for Identification of Early Recurrence in Patients Treated With Radiotherapy for Glioblastoma,Glioblastomas,Not Applicable,Diagnostic
DCTPepD0020,NCT03675451,PSMA Imaging of Localized Prostate Cancer,Prostate Cancer,Phase 2,Diagnostic
DCTPepD0020,NCT05214820,Clinical Assessment of the Therapeutic Potential of 177Lu-PSMA Endoradiotherapy for the Treatment of Upper Metastatic Gastric Cancers Using 68Ga-PSMA PET-based Dosimetry,Upper Digestive Tract Cancer,Phase 2,Diagnostic
DCTPepD0020,NCT02918357,Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence,Prostate Cancer,Phase 2/3,Diagnostic
DCTPepD0020,NCT02919111,Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients,Prostate Cancer,Phase 2/3,Diagnostic
DCTPepD0021,NCT05143229,Phase I Trial Of Alpelisib Plus Sacituzumab Govitecan In Patients With Metastatic Or Locally Recurrent HER2-Negative Breast Cancer,Breast Cancer,Phase 1,Treatment
DCTPepD0021,NCT02058381,A Phase Ib Dose De-escalation Study of the Combination of Tamoxifen Plus Goserelin Acetate With Alpelisib (BYL719) or Buparlisib (BKM120) in Premenopausal Patients With Hormone Receptor-positive/HER2-negative Locally Advanced or Metastatic Breast Cancer,Pre-menopausal Breast Cancer; PI3K Pathway Inhibition,Phase 1,Treatment
DCTPepD0021,NCT04524000,"A Phase II Open-label, 2-Part, Multi-center Study of BYL719 (Alpelisib) in Combination With Fulvestrant for Men and Postmenopausal Women With PIK3CA Mutation Hormone Receptor (HR) Positive, HER2-negative, Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor (AI) Treatment in Japan",Advanced Breast Cancer,Phase 2,Treatment
DCTPepD0021,NCT04753203,"A Phase lb/ll, Open Label, Single Arm Study to Assess Efficacy and Safety of Alpelisib and Capecitabine in Patients With PIK3CA Mutant Metastatic Colorectal Cancer Who Failed Two Prior Standard Chemotherapies",Metastatic Colorectal Cancer; PIK3CA Gene Mutation,Phase 1/2,Treatment
DCTPepD0021,NCT04526470,Phase IB/II Study of Alpelisib in Combination With Paclitaxel in Patients With PIK3CA-altered Metastatic/Recurrent Gastric Cancer,Solid Tumor; Stomach Cancer,Phase 1/2,Treatment
DCTPepD0022,NCT00285701,Early Detection of Pre-malignant and Malignant Conditions in the Colon by Means of Fluorescence Endoscopy Using Local and Oral Sensitisation With Hexaminolevulinate (HAL) - a Dose Finding Study,Colorectal Cancer,Phase 1/2,Diagnostic
DCTPepD0022,NCT01256424,A Randomized Phase II Dose-finding Study of Hexaminolevulinate (HAL) Photodynamic Therapy (PDT) in Patients With Low/Moderate-grade Cervical Intraepithelial Neoplasia (CIN1 or 2),Cervical Intraepithelial Neoplasia,Phase 2,Treatment
DCTPepD0022,NCT00785694,Recurrence of Bladder Cancer After Transurethral Resection With Hexvix,Bladder Cancer,Phase 4,Diagnostic
DCTPepD0022,NCT00412971,"A Randomized, Comparative Phase III, 2-center Study of Hexvix Fluorescence Cystoscopy and Standard Cystoscopy in Patients With Non-invasive Bladder Cancer",Bladder Cancer,Phase 3,Diagnostic
DCTPepD0022,NCT01303991,A Phase I Feasibility Study of Hexvix Photodynamic Therapy in Patients With Intermediate or High-risk Bladder Cancer,Intermediate or High-risk Bladder Cancer,Phase 1,Treatment
DCTPepD0023,NCT04176393,"A Phase 1, Multicenter, Single-Arm Study Evaluating Pharmacokinetic, Pharmacodynamic, Safety, and Clinical Efficacy of Orally Administered Ivosidenib in Chinese Subjects With Relapsed or Refractory Acute Myeloid Leukemia With an IDH1 Mutation",Relapsed or Refractory Acute Myeloid Leukemia,Phase 1,Treatment
DCTPepD0023,NCT03564821,A Phase 1 Study of IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation,IDH1 Mutation Myeloid Neoplasms,Phase 1,Treatment
DCTPepD0023,NCT04056910,Phase II Study of IDH1 Inhibitor Ivosidenib and Nivolumab in IDH1 Mutant Gliomas and Advanced Solid Tumors,Advanced Solid Tumor; IDH1 Mutation; Glioma,Phase 2,Treatment
DCTPepD0023,NCT02073994,"A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation",Cholangiocarcinoma; Chondrosarcoma; Glioma; Other Advanced Solid Tumors,Phase 1,Treatment
DCTPepD0023,NCT03245424,Expanded Access Program for Ivosidenib (AG-120) Monotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH1 Mutation,Acute Myeloid Leukemia; Relapsed Adult AML; Relapsed Pediatric AML,,Treatment
DCTPepD0024,NCT04620239,Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (Padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer,Transitional Cell Cancer of Renal Pelvis and Ureter,Phase 3,Treatment
DCTPepD0024,NCT03617003,Phase I Study of WST11 Phototherapy for Upper Tract Urothelial Carcinoma,Upper Tract Urothelial Carcinoma,Phase 1,Treatment
DCTPepD0024,NCT00975429,Vascular-Targeted Photodynamic Therapy Using WST11 in Patients With Localized Prostate Cancer,Prostate Cancer,Phase 2,Treatment
DCTPepD0024,NCT01573156,Vascular Targeted Photodynamic Therapy With WST11 for T1a Renal Tumours. PHASE IIa Histological Follow up Trial,Renal Cancer,Phase 1/2,Treatment
DCTPepD0024,NCT03133650,A Phase I Trial of Vascular-Targeted Photodynamic Therapy in Esophagogastric Cancer Patients With Moderate to Severe Dysphagia,Esophagogastric Cancer; Moderate to Severe Dysphagia,Phase 1,Treatment
DCTPepD0025,NCT03955042,Pilot Study of Pemetrexed for the Treatment of Chordoma,Chordoma,Phase 1,Treatment
DCTPepD0025,NCT05209620,"A Single Arm, Phase II Clinical Trial of Orelabrutinib Combined With Pemetrexed in the Treatment for Patients With Relapsed/Refractory Central Nervous System Lymphoma",Central Nervous System Lymphoma,Phase 2,Treatment
DCTPepD0025,NCT02588781,Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study,Colorectal Cancer,Phase 2,Treatment
DCTPepD0025,NCT03023319,Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors,"Carcinoma, Non-Small-Cell Lung; Mesothelioma; Bladder Cancer; Ovarian Cancer; Peritoneal Cancer; Thymoma; Thymus Cancer; Uterine Cervical Cancer",Phase 1,Treatment
DCTPepD0025,NCT00712062,Pilot Study to Determine Therapeutic Response of Pemetrexed (Alimta) in Recurrent or Progressive Primary Central Nervous System Lymphoma (PCNSL) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria,Primary Central Nervous System Lymphoma,Phase 2,Treatment
DCTPepD0026,NCT02594267,"A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)",Peripheral T-Cell Lymphoma (PTCL),Phase 1,Treatment
DCTPepD0026,NCT00554827,"A Phase 1, Open-label Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma",Cutaneous T-cell Lymphoma,Phase 1,Treatment
DCTPepD0026,NCT01532011,A Phase I Dose-Escalation Study of Erlotinib in Combination With Pralatrexate in Subjects With Advanced Cancer,Advanced Cancers; Solid Tumors,Phase 1,Treatment
DCTPepD0026,NCT01183065,A Multi-Institution Phase II Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC),Head and Neck Cancer,Phase 2,Treatment
DCTPepD0026,NCT00606502,"A Randomized, Phase 2b, Multi-center Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non-small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-based Treatment",Non-small Cell Lung Cancer,Phase 2,Treatment
DCTPepD0027,NCT03770000,"An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of Tenalisib (RP6530), a Novel PI3K δ/γ Dual Inhibitor Given in Combination With a Histone Deacetylase (HDAC) Inhibitor, Romidepsin in Adult Patients With Relapsed/Refractory T-cell Lymphoma",T Cell Lymphoma,Phase 1/2,Treatment
DCTPepD0027,NCT01537744,"Phase I Trial of Oral 5-azacitidine With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma",Solid Tumors; Virally Mediated Cancers and Liposarcoma,Phase 1,Treatment
DCTPepD0027,NCT01353664,"An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols",Lymphoma; Cancer,Phase 2,Treatment
DCTPepD0027,NCT01913119,A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell,Histologically Proven Extranodal NKTcell Lymphoma,Early Phase 1,Treatment
DCTPepD0027,NCT03355768,Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL),"Lymphoma, T-Cell, Peripheral",Phase 3,Other
DCTPepD0028,NCT05113537,Phase I/II Study of CDK4/6 Inhibition With Abemaciclib to Upregulate PSMA Expression Prior to 177Lu-PSMA-617 Treatment in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Chemotherapy,Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Metastatic Castration-resistant Prostate Carcinoma; Metastatic Castration-resistant Prostate Cancer,Phase 1/2,Treatment
DCTPepD0028,NCT05658003,"An Open-label, Multi-center, Randomized, Phase II Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer",Metastatic Castration-Resistant Prostate Cancer (mCRPC),Phase 2,Treatment
DCTPepD0029,NCT03083613,Phase II Trial of Raltitrexed and Paclitaxel as Second-line Chemotherapy for Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma,Gastric Cancer; Gastroesophageal Junction Adenocarcinoma,Phase 2,Treatment
DCTPepD0029,NCT00004254,Phase II Study on Tomusex in Malignant Mesothelioma,Malignant Mesothelioma,Phase 2,Treatment
DCTPepD0029,NCT05231382,"A Prospective, Multicenter, Phase III Clinical Study Comparing Continuous Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma",Hepatocellular Carcinoma,Phase 3,Treatment
DCTPepD0029,NCT02562599,Study Of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Raltitrexed-Cisplatin for Patients With Locally Advanced Nasopharyngeal Carcinoma,Nasopharyngeal Carcinoma,Phase 2,Treatment
DCTPepD0029,NCT03196843,Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial,Head and Neck Squamous Cell Carcinoma,Phase 4,Treatment
DCTPepD0030,NCT00421811,"An Open-Label, Multicenter, Phase 1/2 Dose Escalation Study to Evaluate Safety, Tolerability and Anti-tumor Activity of Systemic ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan in Subjects With Locally Advanced In-Transit Malignant Melanoma (Adherex Protocol Number AHX-01-007).",Neoplasms,Phase 1/2,Treatment
DCTPepD0030,NCT00265057,"Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Weekly in 3 Week Cycles by Intravenous Infusion in Patients With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX-01-004)",Neoplasms,Phase 1/2,Treatment
DCTPepD0030,NCT00264433,"An Open-Label Phase 2a Study in Subjects With N-Cadherin Positive, Advanced or Recurrent Solid Tumors to Investigate the Safety and Efficacy of ADH-1 Administered Intravenously as a Single Agent (Adherex Protocol Number AHX-01-201)",Neoplasms,Phase 2,Treatment
DCTPepD0030,NCT00390676,"A Phase 1, Multicenter, Dose-Escalation Study to Investigate the Safety and Tolerability of ADH-1 in Combination With 1) Carboplatin or 2) Docetaxel or 3) Capecitabine in Subjects With N-Cadherin Positive, Advanced Solid Tumors (Adherex Protocol Number AHX-01-006)",Neoplasms,Phase 1,Treatment
DCTPepD0030,NCT00225550,"Dose Finding, Safety, Pharmacokinetic and Pharmacodynamic Study of the Vascular Targeting Agent Exherin™ (ADH-1) Administered Once Daily for 5 Consecutive Days by Intravenous Infusion in Subjects With N-Cadherin Expressing, Incurable, Solid Tumors (Adherex Protocol Number AHX 01 003)",Neoplasms,Phase 1/2,Treatment
DCTPepD0031,NCT00131651,"A Dose-Ranging, Phase II, Open Label Study of ATN 161 in Advanced Renal Cell Cancer","Carcinoma, Renal Cell",Phase 2,Treatment
DCTPepD0031,NCT00352313,A Phase I/II Study of ATN-161 and Carboplatin in Adult Patients With Recurrent Intracranial Malignant Glioma,Brain and Central Nervous System Tumors,Phase 1/2,Treatment
DCTPepD0032,NCT01148108,"Phase 2 Study of Canfosfamide HCl for Injection (Telcyta®, TLK286)in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM)",Mantle Cell Lymphoma; B Cell Lymphoma; Multiple Myeloma,Phase 2,Treatment
DCTPepD0032,NCT00022347,A Phase II Study of TLK 286 in Platinum Resistant Advanced Epithelial Ovarian Cancer,Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Phase 2,Treatment
DCTPepD0032,NCT00036920,Phase II Study Of TLK286 For The Treatment Of Advanced Non-Small Cell Lung Cancer,Lung Cancer,Phase 2,Treatment
DCTPepD0032,NCT00350948,Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5),Ovarian Neoplasms,Phase 3,Treatment
DCTPepD0033,NCT03812874,Phase I/II Study of PTX-9908 Injection as an Inhibitor of Cancer Progression in Patients With Non-resectable Hepatocellular Carcinoma Following Transarterial Chemoembolization Treatment,"Carcinoma, Hepatocellular",Phase 1/2,Treatment
DCTPepD0034,NCT01139359,A Phase I Dose Escalation Study of Darinaparsin in Combination With CHOP in Previously Untreated Patients With Lymphomas Who Are Scheduled to Receive CHOP Alone,Lymphoma,Phase 1,Treatment
DCTPepD0034,NCT01139346,Phase I Study of Oral Darinaparsin in Advanced Solid Tumors,Advanced Solid Tumors,Phase 1,Treatment
DCTPepD0034,NCT00421213,Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers,Hematologic Neoplasms; Bone Marrow Neoplasms; Non-Hodgkin's Lymphoma,Phase 2,Treatment
DCTPepD0034,NCT00423306,A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma,Hepatocellular Carcinoma,Phase 2,Treatment
DCTPepD0034,NCT00509782,Phase I Trial of ZIO-101 in Patients With Solid Tumors,Solid Tumors,Phase 1,Treatment
DCTPepD0035,NCT00003677,Phase II Study of Dolastatin 10 (NSC# 376128) Administered Intravenously Every 21 Days to Patients With Metastatic Pancreatic Adenocarcinoma,Pancreatic Cancer,Phase 2,Treatment
DCTPepD0035,NCT00003778,Phase II Trial of Dolastatin-10 in Patients With Previously Untreated Recurrent/Metastatic Sarcoma,Ovarian Cancer; Sarcoma,Phase 2,Treatment
DCTPepD0035,NCT00003557,A Phase II Trial of Dolastatin-10 (NSC 376128) Administered as an IV Bolus Every 3 Weeks in Patients With Hepatobiliary Cancer,Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Liver Cancer,Phase 2,Treatment
DCTPepD0035,NCT00003914,Phase II Study of Dolastatin-10 in Patients With Advanced Renal Cell Carcinoma,Kidney Cancer,Phase 2,Treatment
DCTPepD0035,NCT00003693,"Phase I Study of Dolastatin-10 in Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase",Leukemia; Myelodysplastic Syndromes,Phase 1,Treatment
DCTPepD0036,NCT01994369,A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Surgery Presenting Breast Cancer,Resectable Breast Cancer,Phase 1,Diagnostic
DCTPepD0036,NCT02000778,A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Intraoperative Detection of Occult Ovarian Carcinoma,Ovarian Cancer,Phase 1,Diagnostic
DCTPepD0036,NCT01778933,A Pilot and Feasibility Study Of The Imaging Potential Of EC17 In Subjects Undergoing Surgery Presenting With Renal Nodules,Renal Cell Carcinoma,Phase 1,Diagnostic
DCTPepD0036,NCT01778920,Intraoperative Imaging of Pulmonary Adenocarcinoma,Lung and Pleural Malignancies; Neoplasms; Nodules; Adenocarcinoma,Phase 1,Diagnostic
DCTPepD0036,NCT00485563,A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma,Renal Cell Carcinoma,Phase 1,Treatment
DCTPepD0037,NCT02020291,"Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colon or Prostate Cancer",Metastatic Breast Cancer; Colorectal Cancer; Prostate Cancer,Phase 1,Treatment
DCTPepD0037,NCT02655952,"Phase Ib Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacodynamic Response of Foxy-5 in Patients With Metastatic Breast-, Colon- or Prostate Cancer",Metastatic Breast Cancer; Metastatic Colon Cancer; Metastatic Prostate Cancer,Phase 1,Treatment
DCTPepD0037,NCT03883802,"A Randomized, Multicentre, Open-Label Controlled Phase II Trial of Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer",Colon Cancer,Phase 2,Treatment
DCTPepD0038,NCT01968915,A Phase I Study of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors,Neoplasms,Phase 1,Treatment
DCTPepD0038,NCT01955434,Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma,Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma,Phase 2,Treatment
DCTPepD0038,NCT02098161,"Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)","Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis; Secondary Myelofibrosis",Phase 2,Treatment
DCTPepD0038,NCT01934634,"Phase I Trial of the Proapoptotic Agonist, LCL161, and Gemcitabine Plus Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer",Metastatic Pancreatic Cancer,Phase 1,Treatment
DCTPepD0038,NCT01240655,A Phase Ib Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors,Solid Tumors,Phase 1,Treatment
DCTPepD0039,NCT00290953,"A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Versus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin + Etoposide",Lung Cancer; Pulmonary Neoplasms; Small Cell Lung Cancer,Phase 2/3,Treatment
DCTPepD0040,NCT00003773,Phase I Study of Escalating Doses of IM-862 in Patients With Ovarian Cancer,Ovarian Cancer,Phase 1,Treatment
DCTPepD0040,NCT00006037,Phase II Randomized Placebo-Controlled Double-Blinded Study With 5-FU vs. 5-FU With IM862 With Cross-Over to CPT-11 vs. CPT-11 With IM862,Colorectal Cancer,Phase 2,Treatment
DCTPepD0040,NCT00017303,A Phase II Trial Of IM862 Combined With Paclitaxel And Carboplatin In Newly Diagnosed Advanced Epithelial Ovarian Or Primary Peritoneal Carcinoma Followed By IM862 Consolidation Therapy,Ovarian Cancer; Primary Peritoneal Cavity Cancer,Phase 2,Treatment
DCTPepD0041,NCT00695851,"A Phase I Randomized Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.",Prostate Cancer,Phase 1,Treatment
DCTPepD0042,NCT01013324,A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma,Endometrial Cancer; Endometrial Neoplasms,Phase 2,Treatment
DCTPepD0042,NCT01943838,A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245408 Polymorph E Administered Once Daily to Subjects With Solid Tumors or Lymphoma,Neoplasm Malignant,Phase 1,Treatment
DCTPepD0042,NCT00486135,A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL147 Administered Orally Daily to Subjects With Solid Tumors or Lymphoma,Cancer; Lymphoma,Phase 1,Treatment
DCTPepD0042,NCT01042925,A Phase 1/2 Study of XL147 (SAR245408) Administered in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen,Breast Cancer; Breast Neoplasms,Phase 1/2,Treatment
DCTPepD0042,NCT00692640,A Phase 1 Dose-Escalation Study of XL147 (SAR245408) in Combination With Erlotinib in Subjects With Solid Tumors,Cancer; Non-small Cell Lung Cancer,Phase 1,Treatment
DCTPepD0043,NCT00040755,"Randomized Phase II Trial of BMS-275291 (NSC 713763, IND 62573) in Hormone Refractory Prostate Cancer",Adenocarcinoma of the Prostate; Bone Metastases; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Phase 2,Treatment
DCTPepD0043,NCT00039104,"A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa™) and BMS-275291 (NSC#713763) in Patients With Hormone Refractory Prostate Cancer",Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer,Phase 2,Treatment
DCTPepD0043,NCT00024024,A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma,Sarcoma,Phase 1/2,Treatment
DCTPepD0043,NCT00006229,A Phase II/III Double Blind Randomized Trial of BMS-275291 vs. Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer,Lung Cancer,Phase 2/3,Treatment
DCTPepD0044,NCT03784677,A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors,Advanced Malignant Solid Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Ovarian Carcinoma; Refractory Pancreatic Carcinoma; Stage II Pancreatic Cancer AJCC v8; Stage IIA Pancreatic Cancer AJCC v8; other various stages of Pancreatic Cancer and Ovarian Carcinoma,Phase 1,Treatment
DCTPepD0044,NCT01578564,"Phase I, Open-label, Dose Escalation Study to Assess Safety and Tolerability of SOR-C13 in Subjects With Advanced Solid Tumors Commonly Known to Express the TRPV6 Ion Channel",Cancer,Phase 1,Treatment
DCTPepD0045,NCT00078390,"A Phase I/II Study of the Safety, Pharmacokinetic Interaction and Efficacy of S-3304 in Combination With Standard Therapy in Patients With Locally Advanced Non-small Cell Lung Cancer.",Non Small Cell Lung Cancer; Lung Cancer; Stage IIIA Non Small Cell Lung Cancer; Stage IIIB Non Small Cell Lung Cancer,Phase 1/2,Treatment
DCTPepD0045,NCT00033566,A Phase I Study of S-3304 in Patients With Solid Tumors,"Unspecified Adult Solid Tumor, Protocol Specific",Phase 1,Treatment
DCTPepD0045,NCT00033215,A Phase 1 Study of S-3304 in Patients With Solid Tumors,Solid Tumors,Phase 1,Treatment
DCTPepD0046,NCT00080080,Phase 2 Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer,Lung Cancer,Phase 2,Treatment
DCTPepD0046,NCT04171219,"A Phase 2 Basket Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination With Pembrolizumab in Patients With Advanced Solid Cancers",Advanced Malignant Solid Neoplasm; Recurrent Malignant Solid Neoplasm,Phase 2,Treatment
DCTPepD0046,NCT00489710,A Phase II Study of Talabostat in Patients With Metastatic Renal Cell Carcinoma,Kidney Cancer,Phase 2,Treatment
DCTPepD0046,NCT04123574,"A Pilot Proof of Mechanism Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPPs), in Patients With Pancreatic Cancer","Cancer of Pancreas; Cancer of the Pancreas; Neoplasms, Pancreatic; Pancreas Cancer; Pancreatic Cancer",Early Phase 1,Treatment
DCTPepD0046,NCT00290017,"A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Pemetrexed vs. Pemetrexed and Placebo in Patients With Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy","Carcinoma, Non-Small-Cell Lung; Lung Cancer; Neoplasms, Lung; Neoplasms, Pulmonary",Phase 3,Treatment
DCTPepD0047,NCT00780598,"The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects With Treatment Refractory or Relapsed Acute Myeloid Leukemia",Acute Myeloid Leukemia; AML,Phase 2,Treatment
DCTPepD0047,NCT00689000,"A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia or Multiple Myeloma",Acute Myeloid Leukemia; Myelodysplastic Syndrome; Multiple Myeloma,Phase 1/2,Treatment
DCTPepD0047,NCT02452346,Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Atients With Myelodysplastic Syndromes (MDS) After Failure of Hypomethylating Agent-Based Therapy,Myelodysplastic Syndrome,Phase 2,Treatment
DCTPepD0047,NCT01180426,The TOPAZ Study: A Long-Term Extension Study in Elderly Subjects With Relapsed/Refractory Acute Myeloid Leukemia to Allow Continued Therapy With Tosedostat,Acute Myeloid Leukemia,Phase 3,Treatment
DCTPepD0047,NCT00737555,A Phase 1b Dose-escalation Study to Evaluate the Safety and Tolerability of the Addition of the Aminopeptidase Inhibitor CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours,Solid Tumor,Phase 1,Treatment
DCTPepD0048,NCT00165802,A Phase I Open Label Study of E7974 Administered on Day 1 of a 21-Day Cycle In Patients With Advanced Solid Tumors,"Cancer, Malignant Tumors",Phase 1,Treatment
DCTPepD0048,NCT00130169,A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies,"Cancer, Malignant Tumors",Phase 1,Treatment
DCTPepD0048,NCT00121732,"A Phase 1, Two-Arm, Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies","Cancer, Malignant Tumors",Phase 1,Treatment
DCTPepD0049,NCT00622622,"Phase I Study of Gemcitabine With Antiangiogenic Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*2402 Derived From VEGFR2 in Patients With Unresectable, Locally Advanced, Recurrent or Metastatic Pancreatic Cancer",Pancreatic Cancer,Phase 1,Treatment
DCTPepD0049,NCT00639925,"Phase I Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer",Pancreatic Cancer,Phase 1,Treatment
DCTPepD0049,NCT00655785,"Phase I/II Sturdy on Antiangiogenic Vaccine Therapy Using Epitope Peptide Derived From VEGFR1 and VEGFR2 With Gemcitabine in Treating Patients With Unresectable, Recurrent, or Metastatic Pancreatic Cancer",Pancreatic Cancer,Phase 1/2,Treatment
DCTPepD0050,NCT04826016,A Phase Ib/II Study to Optimize POL6326 (Balixafortide) in Combination With Nab-paclitaxel or Eribulin in Patients With HER2-negative Advanced Breast Cancer,Advanced Breast Cancer,Phase 1/2,Treatment
DCTPepD0050,NCT01837095,"A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer",Metastatic Breast Cancer,Phase 1,Treatment
DCTPepD0050,NCT01413568,A Phase I/II Study Evaluating the Safety and Efficacy of Intravenous POL6326 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies,"Acute Myeloid Leukemia in Remission; Adult Acute Lymphoblastic Leukemia in Remission; Chronic Myelogenous Leukemia (CML); Non-Hodgkin's Lymphoma (NHL) or Hodgkin's Disease (HD) in 2nd or  Greater Complete Remission, Partial Remission; Chronic Lymphocytic Leukemia (CLL); Multiple Myeloma (MM); Myelodysplastic Syndrome (MDS); Myeloproliferative Disorders",Phase 1/2,Treatment
DCTPepD0050,NCT03786094,"An International, Phase 3, Multicenter, Randomized, Open- Label Trial Comparing Balixafortide in Combination With Eribulin Versus Eribulin Alone in Patients With HER2 Negative, Locally Recurrent or Metastatic Breast Cancer",Metastatic Breast Cancer; Locally Recurrent Breast Cancer,Phase 3,Treatment
DCTPepD0050,NCT01905475,"CXCR4 AnTagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI). A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients With Large Reperfused ST Elevation Myocardial Infarction",Large Reperfused ST-Elevation Myocardial Infarction,Phase 2,Treatment
DCTPepD0051,NCT01660399,"Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial",Squamous Cell Lung Cancer,Phase 2,Treatment
DCTPepD0052,NCT01986218,"Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors",Various Advanced Cancer,Phase 1,Treatment
DCTPepD0053,NCT01517776,Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study HIT-HGG-CilMetro - A Clinical Phase II Trial of the HIT-HGG Study Group -,Gliomas,Phase 2,Treatment
DCTPepD0053,NCT01118676,Phase I Trial Evaluating Continuous Infusion of Cilengitide Together With Radiochemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer,Locally Advanced Non Small Cell Lung Cancer (NSCLC),Phase 1,Treatment
DCTPepD0053,NCT01782976,A Phase II Trial of Cilengitide Plus Bevacizumab in Patients With Recurrent Glioblastoma,Glioblastoma,Phase 2,Treatment
DCTPepD0053,NCT00121238,"Phase II Evaluation of EMD 121974 (NSC 707544, Cilengitide) in Patients With Non-Metastatic Androgen Independent Prostate Cancer",Recurrent Prostate Cancer; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer; Stage III Prostate Cancer,Phase 2,Treatment
DCTPepD0053,NCT00093964,"A Multicenter, Open-label, Randomized, Uncontrolled, Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity, Safety, and Tolerability of Cilengitide (EMD 121,974) Administered as a Single Agent.",Glioblastoma Multiforme,Phase 2,Treatment
DCTPepD0054,NCT01815515,Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer.,Metastatic Prostate Cancer,Phase 1/2,Diagnostic
DCTPepD0054,NCT01417182,Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFBC PSMA Based PET in Patients With Advanced Prostate Cancer,Prostate Cancer,Phase 1,Screening
DCTPepD0054,NCT02190279,A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer,Prostatic Neoplasms; Prostate Cancer,Early Phase 1,Diagnostic
DCTPepD0054,NCT01496157,Evaluation of PSMA-based PET as an Imaging Biomarker of Primary Prostate Cancer,Prostate Cancer,Phase 1/2,Diagnostic
DCTPepD0055,NCT03014076,Phase Ib Trial of Combination Immunotherapy With HER2/Neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients,Breast Cancer,Phase 1,Treatment
DCTPepD0055,NCT00524277,Phase II Trial of the HER2/Neu Peptide GP2 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2+ OR the Modified HER2/Neu Peptide AE37 + GM-CSF Vaccine vs GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients,Breast Cancer,Phase 2,Prevention
DCTPepD0055,NCT05232916,"A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)",Breast Cancer,Phase 3,Prevention
DCTPepD0056,NCT00357461,A Randomized Phase II Study of Fixed Dose Ipilimumab (MDX-010) 10 mg/kg Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 VG for Previously Treated HLA-A * 0201 Positive Subjects With Stage IV Melanoma,Melanoma (Skin),Phase 1,Treatment
DCTPepD0056,NCT01176461,A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma,Melanoma (Skin),Phase 1,Treatment
DCTPepD0056,NCT01176474,A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,Melanoma (Skin),Phase 1,Treatment
DCTPepD0057,NCT00064220,"A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy",Sarcoma,Phase 2,Treatment
DCTPepD0057,NCT00061854,"A Phase II Study Of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, To Patients With Progressive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) Following Treatment With Platinum-Based Chemotherapy",Lung Cancer,Phase 2,Treatment
DCTPepD0057,NCT00072228,Phase I Study of Soblidotin and Gemcitabine in Patients With Locally Advanced or Metastatic Solid Tumors,"Unspecified Adult Solid Tumor, Protocol Specific",Phase 1,Treatment
DCTPepD0058,NCT01423760,An Open-label Trial to Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials,Non-Small Cell Lung Cancer; Multiple Myeloma,Not Applicable,Treatment
DCTPepD0058,NCT01496131,"A Randomized Phase II Study of Tecemotide in Combination With Standard Androgen Deprivation Therapy and Radiation Therapy for Untreated, Intermediate and High Risk Prostate Cancer Patients",Prostate Cancer,Phase 2,Treatment
DCTPepD0058,NCT00157196,"A Multi-center, Non-randomized, Open Label Safety Study of BLP25 Liposome Vaccine (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Patients With Unresectable Stage III Disease","Carcinoma, Non-Small-Cell Lung; Lung Neoplasms",Phase 2,Treatment
DCTPepD0058,NCT01507103,"A Multi-center, Randomized, Open-label, Mechanism of Action Trial on the Biological Effects of the Therapeutic Cancer Vaccine Stimuvax® (L-BLP25) in Rectal Cancer Subjects Undergoing Neoadjuvant Chemoradiotherapy",Rectal Cancer,Phase 2,Treatment
DCTPepD0058,NCT00157209,"A Multicenter Phase IIb Randomised, Controlled Study of BLP25 Liposome Vaccine for Active Specific Immunotherapy of Non-Small Cell Lung Cancer","Lung Neoplasms; Carcinoma, Non-Small-Cell Lung",Phase 2,Treatment
DCTPepD0059,NCT02700529,"Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)",Lymphedema,Phase 2,Treatment
DCTPepD0060,NCT00014651,"Vapreotide in Pancreas Surgery: A Double-Blind, Placebo-Controlled, Randomized Study of Vapreotide to Prevent Post-Surgical Complications in Patients Undergoing Elective Pancreatic Resection Grant Application Title: Vapreotide to Prevent Complications of Pancreatic Resection",Pancreatic Cancer; Perioperative/Postoperative Complications,Phase 3,Supportive Care
DCTPepD0060,NCT00331188,The Early Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension,Esophageal Varices; Portal Hypertension; Gastric Varices; Esophageal Bleeding,Phase 3,Treatment
DCTPepD0061,NCT00113334,A Phase 1b/2 Study of ABT-510 (Thrombospondin Analogue) in Patients With Advanced Head and Neck Cancer,Head and Neck Cancer,Phase 1/2,Treatment
DCTPepD0061,NCT00584883,A Phase I Study of ABT 510 and Concurrent Temozolomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme,Brain Tumor,Phase 1,Treatment
DCTPepD0061,NCT00073125,A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma,"Carcinoma, Renal Cell",Phase 2,Treatment
DCTPepD0061,NCT00061672,A Phase II Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma,"Lymphoma, Non-Hodgkin; Hodgkin's Lymphoma",Phase 2,Treatment
DCTPepD0061,NCT00061659,A Phase II Randomized Study Evaluating the Safety and Efficacy of ABT-510 in Subjects With Locally Advanced or Metastatic Soft Tissue Sarcoma,"Sarcoma, Soft Tissue",Phase 2,Treatment
DCTPepD0062,NCT00273936,A Phase I Trial of AVN-944 in Patients With Advanced Hematologic Malignancies,Acute Leukemia; Chronic Leukemia; Multiple Myeloma; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Waldenstrom's Macroglobulinemia,Phase 1,Treatment
DCTPepD0062,NCT00923728,"A Phase 1 Trial of AVN944, an IMPDH Inhibitor, in Adults With Advanced Stage Solid Tumors",Refractory Solid Tumors,Not Applicable,Treatment
DCTPepD0062,NCT00493441,A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer,Pancreatic Cancer,Phase 2,Treatment
DCTPepD0063,NCT04461600,"A Phase 2, Multi-center, Open-label, Single Arm Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer",Triple Negative Breast Cancer,Phase 2,Treatment
DCTPepD0063,NCT03691207,"A Phase 2, Open-Label, Multi-center Study of AL101 in Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations",Adenoid Cystic Carcinoma,Phase 2,Treatment
DCTPepD0063,NCT04973683,AL101 Prior to Standard-of-Care Surgery in Patients With Notch Activated Adenoid Cystic Carcinoma (ACC),Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma,Phase 1,Treatment
DCTPepD0064,NCT00088166,"A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated With Peritumoral Brain Edema in Patients With Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone",Brain Edema; Brain Tumor,Phase 3,Treatment
DCTPepD0065,NCT02636582,VADIS Trial: Phase II Trial of Nelipeimut-S Peptide Vaccine in Women With DCIS of the Breast,Breast Ductal Carcinoma In Situ,Phase 2,Prevention
DCTPepD0065,NCT02297698,Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients,Breast Cancer,Phase 2,Prevention
DCTPepD0065,NCT01479244,"PRESENT: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax™Treatment",Breast Cancer With Low to Intermediate HER2 Expression,Phase 3,Prevention
DCTPepD0065,NCT01570036,Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence,Breast Cancer,Phase 2,Prevention
DCTPepD0066,NCT00118781,"Randomized, Double-Blind, Placebo-Controlled, Multinational Phase 3 Trial Of Iseganan In Prevention Of Ventilator-Associated Pneumonia",Pneumonia,Phase 2/3,Prevention
DCTPepD0066,NCT00022373,"A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy",Head and Neck Cancer; Oral Complications of Radiation Therapy; Radiation Toxicity,Phase 3,Supportive Care
DCTPepD0067,NCT00005602,Phase I Study of Concurrent Cereport and Carboplatin With Radiation Therapy for Children With Newly-Diagnosed Brain Stem Gliomas,Brain and Central Nervous System Tumors,Phase 1,Treatment
DCTPepD0067,NCT00001502,Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors,Brain Neoplasms; Glioma; Medulloblastoma,Phase 1,Treatment
DCTPepD0067,NCT00019422,A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors,Brain and Central Nervous System Tumors,Phase 2,Treatment
DCTPepD0067,NCT00002316,Phase I Study to Evaluate the Safety and Tolerance of RMP-7 Administered With Amphotericin B to Patients With HIV Infection and Cryptococcal Meningitis,"Meningitis, Cryptococcal; HIV Infections",Phase 1,Treatment
DCTPepD0068,NCT00681486,"Ghrelin - A Possible Opportunity to Improve Appetite, Nutritional State, Metabolic Integrity and Physical Functioning in Cancer Patients With Progressive Weight Loss",Cancer,Phase 3,Treatment
DCTPepD0068,NCT00933361,Individual Dose-escalated Bi-daily sc Ghrelin in Cancer Cachexia: a Phase I/II Study,Advanced Cancer； Cachexia,Phase 1/2,Treatment
DCTPepD0068,NCT02913703,Effect of Preprandial Ghrelin on Postprandial Glucose Tolerance,Type 2 Diabetes,Phase 1,Basic Science
DCTPepD0069,NCT01777594,"A Phase II, Multicenter, Single-Arm Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib for Adult Patients With Progressive Advanced Hepatocellular Carcinoma",Advanced Adult Hepatocellular Carcinoma,Phase 2,Treatment
DCTPepD0069,NCT02067156,"An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma",Glioblastoma Multiforme,Phase 2,Treatment
DCTPepD0069,NCT01056029,"An Open Label, Single-Arm, Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors",Advanced Solid Tumors,Phase 1,Treatment
DCTPepD0069,NCT02607553,"G-202-006: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA",Clear Cell Renal Cell Carcinoma,Phase 2,Treatment
DCTPepD0069,NCT02381236,"G-202-005: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 Administered in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Adenocarcinoma of the Prostate",Prostatic Neoplasms,Phase 2,Treatment
DCTPepD0070,NCT03785964,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)",Desmoid Tumor; Aggressive Fibromatosis,Phase 3,Treatment
DCTPepD0070,NCT05348356,A Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell Tumors,Ovarian Granulosa-Stromal Tumor; Ovarian Granulosa Cell Tumor; Ovarian Cancer,Phase 2,Treatment
DCTPepD0070,NCT05556798,Belantamab Mafodotin in Combination With Nirogacestat in Patients With Relapsed or Refractory Multiple Myeloma,Multiple Myeloma,Phase 1,Treatment
DCTPepD0071,NCT00427219,"A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS) Due to Benign Prostatic Hypertrophy (BPH)",Benign Prostatic Hypertrophy,Phase 2,Treatment
DCTPepD0071,NCT01252693,Phase 2 Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer,Prostate Cancer,Phase 2,Treatment
DCTPepD0071,NCT00743184,"A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)",Benign Prostatic Hyperplasia (BPH); Lower Urinary Tract Symptoms (LUTS),Phase 2,Treatment
DCTPepD0072,NCT03070964,A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma,Lymphoma,Phase 2,Treatment
DCTPepD0072,NCT02100657,Phase I Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma,Multiple Myeloma,Phase 1,Other
DCTPepD0072,NCT01102426,"Randomized, Multicenter, Open-label, Phase III Study of Plitidepsin in Combination With Dexamethasone vs. Dexamethasone Alone in Patients With Relapsed/Refractory Multiple Myeloma",Relapsed/Refractory Multiple Myeloma,Phase 3,Treatment
DCTPepD0072,NCT01876043,"Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial","Adult Patients With Unresectable Locally Advanced or Metastatic, Relapsed/Refractory Dedifferentiated Liposarcoma",Phase 2,Treatment
DCTPepD0072,NCT00788099,"Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas",Advanced Solid Tumors; Lymphomas,Phase 1,Treatment
DCTPepD0073,NCT02369796,"An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Participants With Hypogonadotropic Hypogonadism",Hypogonadotropic Hypogonadism,Phase 2,Treatment
DCTPepD0073,NCT02381288,"A Randomized, Single-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Stimulatory Effects of TAK-448, a Kisspeptin Analog, Administered Intermittently in Middle-aged and Older Men With Low Testosterone",Low Testosterone,Phase 2,Treatment
DCTPepD0073,NCT01132404,"A Phase 1/2, Open Label Study in Men With Prostate Cancer to Assess the Safety. Pharmacokinetics and Testosterone-Lowering Efficacy of TAK-448, Administered as a 1-Month Depot, Including a Randomized Portion With a Group Administered Leuprorelin",Prostate Cancer; Prostatic Neoplasms,Phase 1/2,Treatment
DCTPepD0074,NCT00458744,A Phase I Study Of Talotrexin (PT-523) In Children And Adolescents With Recurrent Solid Tumors Or Recurrent/Refractory Leukemias,"Brain and Central Nervous System Tumors; Leukemia; Lymphoma; Unspecified Childhood Solid Tumor, Protocol Specific",Phase 1,Treatment
DCTPepD0074,NCT00098514,A Phase I Study Of PT523 In Patients With Solid Tumors,"Unspecified Adult Solid Tumor, Protocol Specific",Phase 1,Treatment
DCTPepD0074,NCT00112060,"A Phase I/II, Open-Label, Multicenter Study of Single Agent PT-523 in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)",Non-Small-Cell Lung Carcinoma,Phase 1/2,Treatment
DCTPepD0075,NCT04693507,"An Adaptive Phase 2, Open-Label, Multicentre Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix Trifluoroacetate, a GnRH Antagonist, in Participants With Advanced Prostate Cancer",Prostatic Adenoma,Phase 2,Treatment
DCTPepD0075,NCT03781947,"A Phase I, Open-label, Single Centre Study Investigating the PK, Safety and PD of a Single Dose of Teverelix TFA, a GnRH Antagonist, Via s.c. or i.m. Route of Administration in Healthy Male Volunteers",Healthy,Phase 1,Basic Science
DCTPepD0076,NCT01323517,A Phase II Trial of The Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity,Melanoma,Phase 2,Treatment
DCTPepD0076,NCT00003688,Pulse Actinomycin-D as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Neoplasia,Gestational Trophoblastic Tumor,Phase 2,Treatment
DCTPepD0076,NCT00075582,"Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma",Adult Rhabdomyosarcoma; Embryonal Childhood Rhabdomyosarcoma; Embryonal-botryoid Childhood Rhabdomyosarcoma; Previously Untreated Childhood Rhabdomyosarcoma,Phase 3,Treatment
DCTPepD0076,NCT00245089,Phase II Trial of VAC2.2/VA Therapy for Low-Risk B Group Patients With Rhabdomyosarcoma,Sarcoma,Phase 2,Treatment
DCTPepD0076,NCT00352534,Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor,Stage I Wilms Tumor; Stage II Wilms Tumor; Stage III Wilms Tumor,Phase 3,Treatment
DCTPepD0077,NCT00006466,Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Myeloma,Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition,Phase 1/2,Treatment
DCTPepD0077,NCT00007839,Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With B-Cell Lymphoma,Lymphoma,Phase 1/2,Treatment
DCTPepD0077,NCT00041379,Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia,Lymphoma,Phase 1/2,Treatment
DCTPepD0078,NCT02440308,68Ga-DOTA-Bombesin PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study,Prostate Carcinoma,Phase 2,Diagnostic
DCTPepD0078,NCT03724253,Phase II Study of Preliminary Diagnostic Performance of [68Ga]-NeoBOMB1 in Adult Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR),Breast Cancer; Prostate Cancer; Colorectal Cancer; Non Small Cell Lung Cancer; Small Cell Lung Cancer,Phase 2,Diagnostic
DCTPepD0079,NCT01614990,Cancer Cachexia,Cancer Cachexia,Phase 2,Treatment
DCTPepD0079,NCT03844217,Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers - The Macicop-Study,Polyuria-polydipsia Syndrome,Not Applicable,Diagnostic
DCTPepD0080,NCT00712829,"A Phase I Study Evaluating the Safety, Pharmacokinetics, Tissue Distribution, Metabolism of Small Molecule Inhibitors of Prostate Specific Membrane Antigen: Determination of I-123 Radiation Dosimetry for 123-I-MIP-1072 and 123-I-MIP-1095",Prostate Cancer,Phase 1,Diagnostic
DCTPepD0081,NCT00404521,"A Phase I Single-institution, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM02734 Administered Every 3 Weeks, Intravenously, Over 30 Minutes, to Subjects With Advanced Malignant Solid Tumors.",Solid Tumors,Phase 1,Treatment
DCTPepD0081,NCT00884845,"Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors",Advanced Malignant Solid Tumors,Phase 1,Treatment
DCTPepD0082,NCT00100347,A Phase 1 Dose Escalation Safety/Tolerance Study of PPI-2458 in Subjects With Non-Hodgkin's Lymphoma and Solid Tumors,Non-Hodgkin's Lymphoma; Solid Tumors,Phase 1,Treatment
DCTPepD0083,NCT01807546,"A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma",Head and Neck Squamous Cell Carcinoma; Anal Squamous Cell Carcinoma; Lung Squamous Cell Carcinoma; Cervical Squamous Cell Carcinoma; Esophageal Squamous Cell Carcinoma; Skin Squamous Cell Carcinoma; Penile Squamous Cell Carcinoma,Phase 2,Treatment
DCTPepD0083,NCT04263090,A Phase1/2a Study of Rigosertib Plus Nivolumab in Stage IV Lung Adenocarcinoma Patients With KRAS Mutation Who Progressed on First-Line Treatment,Non-small Cell Lung Cancer; Adenocarcinoma; Stage IV,Phase 1/2,Treatment
DCTPepD0083,NCT02730884,A Phase II Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia,Leukemia; Myelofibrosis; Anemia; Splenomegaly,Phase 2,Treatment
DCTPepD0083,NCT01167166,"A Phase 1/2, Single Arm Study To Assess the Efficacy and Safety of Rigosertib (ON 01910.Na) Administered as 72-Hour and 120-Hour Continuous Intravenous Infusions Every Other Week for Two Cycles Then as Twice Daily Oral Capsules Given Continuously in Patients With Relapsed/Refractory Acute Myeloid or Lymphocytic Leukemia or Transformed Myeloproliferative Neoplasms",Acute Myelocytic Leukemia; Acute Lymphocytic Leukemia; Myeloproliferative Disease; Chronic Myeloid Leukemia,Phase 1/2,Treatment
DCTPepD0083,NCT01168011,"A Phase 1 Study To Assess The Tolerability, Pharmacokinetics and Clinical Activity of Rigosertib Administered Orally as Escalating Multiple Doses Twice or Three Times a Day up to 21 Days of a 21-Day Cycle in Patients With Advanced Cancer",Solid Tumor,Phase 1,Treatment
DCTPepD0084,NCT03512756,A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred,Pancreatic Cancer,Phase 2/3,Treatment
DCTPepD0084,NCT03778996,"A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of SM-88 Used With Methoxsalen, Phenytoin, and Sirolimus (MPS) as Response Maintenance Therapy Following Standard Treatments for Patients With Ewing's Sarcoma or as Salvage Therapy for Patients With Clinically Advanced Sarcomas","Sarcoma, EwingSarcoma",Phase 2,Treatment
DCTPepD0085,NCT00083525,Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies,Advanced Malignancies,Phase 1,Treatment
DCTPepD0086,NCT01767155,"Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.",Endometrial Cancer,Phase 3,Treatment
DCTPepD0086,NCT01698281,"A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.",Breast Cancer,Phase 2,Treatment
DCTPepD0087,NCT00003207,Phase I Study on Doxil and SDZ PSC 833 in the Treatment of AIDS-Associated Kaposi's Sarcoma and Other Advanced Malignancies,"Sarcoma; Unspecified Adult Solid Tumor, Protocol Specific",Phase 1,Treatment
DCTPepD0087,NCT00002912,"A PHASE I COOPERATIVE AGREEMENT PEDIATRIC TRIAL OF MITOXANTRONE, ETOPOSIDE AND PSC-833 (PSC-ME) THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY ACUTE LEUKEMIA",Leukemia,Phase 1,Treatment
DCTPepD0087,NCT00001302,A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833,Breast Cancer; Kidney Neoplasm; Lymphoma; Neoplasm Metastasis; Ovarian Cancer,Phase 1,Treatment
DCTPepD0087,NCT00002937,A Phase II Randomized Study of Paclitaxel Versus Paclitaxel + PSC833 for Advanced Breast Cancer (Recurring Less Than 6 Months Since Adjuvant or as Second Line for Advanced Disease,Breast Cancer,Phase 2,Treatment
DCTPepD0087,NCT00002878,"A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA",Multiple Myeloma and Plasma Cell Neoplasm,Phase 3,Treatment
DCTPepD0088,NCT01058616,Phase 1 Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour,Cancer With Transdermal Accessible Tumour,Phase 1,Treatment
DCTPepD0088,NCT01986426,"A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours",Cancer; Melanoma; Breast Cancer; Head and Neck Cancer; Lymphoma; Triple-Negative Breast Cancer,Phase 1,Treatment
DCTPepD0088,NCT01223209,"A Phase I, Combination, Immunologic Study of LTX-315 as Adjunct to GV1001 in Patients Following Curative Surgery for Carcinoma",Carcinoma,Phase 1,Treatment
DCTPepD0088,NCT04796194,A Phase II Study of Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Patients With Percutaneously Accessible Lesions With Advanced Melanoma Refractory to Pembrolizumab,Advanced Melanoma,Phase 2,Treatment
DCTPepD0088,NCT03725605,An Open Label Phase II Single Centre Study Investigating the Safety and Efficacy of LTX-315 and Adoptive T-cell Therapy in Patients With Advanced/Metastatic Soft Tissue Sarcoma (ATLAS-IT-04),Soft Tissue Sarcoma,Phase 2,Treatment
DCTPepD0089,NCT01267253,A Phase II Evaluation of Brivanib (BMS582664) in the Treatment of Persistent or Recurrent Carcinoma of the Cervix (BMS Study CA182-048),"Cervical Adenocarcinoma; Cervical Adenosquamous Carcinoma; Cervical Squamous Cell Carcinoma, Not Otherwise Specified; Persistent Disease; Recurrent Cervical Carcinoma",Phase 2,Treatment
DCTPepD0089,NCT04212221,"A Multicenter, Open-label, Phase I/II Dose Escalation and Expansion Clinical Study to Assess the Safety and Efficacy of MGD013 Monotherapy and in Combination With Brivanib Alaninate (ZL-2301) in Patients With Advanced Liver Cancer",Advanced Hepatocellular Carcinoma (HCC),Phase 1/2,Treatment
DCTPepD0089,NCT00437437,"Phase I Study to Determine the Effect of a High Fat Meal on the Pharmacokinetics of BMS-540215, the Active Metabolite of Brivanib Alaninate in Subjects With Advanced or Metastatic Solid Tumors",Tumors,Phase 1,Treatment
DCTPepD0089,NCT03516071,"A Multicenter, Randomized, Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Brivanib Alaninate (ZL-2301) Combined With Best Supportive Care (BSC) and Pharmacokinetic Profiles of Brivanib Alaninate in Patients With Advanced Hepatocellular Carcinoma (HCC) Failed or Intolerant of Standard Systemic Chemotherapy and/or Sorafenib",Hepatocellular Carcinoma (HCC),Phase 2,Treatment
DCTPepD0089,NCT03895788,"An Open-Label, Single-Arm, Phase I Clinical Trial to Evaluate the Safety and Tolerability of ZL-2306 (Niraparib) in Combination With Brivanib in Patients With Recurrent Ovarian Cancer",Ovarian Cancer,Phase 1,Treatment
DCTPepD0090,NCT02085460,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer",Head and Neck Cancer,Phase 2,Treatment
DCTPepD0090,NCT02243618,The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer,Gastric Adenoma; Early Gastric Cancer,Not Applicable,Treatment
DCTPepD0090,NCT03608761,"Comparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open Study",Dry Eye Syndromes; Sjögren Syndrome,Phase 4,Treatment
DCTPepD0091,NCT01560923,"A Randomized, Double-Blind Phase II Study of Sipuleucel-T (Provenge®) Followed by Indoximod or Placebo in the Treatment of Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration Resistant Prostate Cancer",Metastatic Prostate Cancer,Phase 2,Treatment
DCTPepD0091,NCT02835729,A Phase 1 Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML),Acute Myeloid Leukemia,Phase 1,Treatment
DCTPepD0091,NCT03301636,A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Adult Patients With Unresectable Stage III or Stage IV Malignant Melanoma,Melanoma,Phase 2/3,Treatment
DCTPepD0091,NCT05106296,Repurposing Ibrutinib for Chemo-Immunotherapy in a Phase 1b Study of Ibrutinib With Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients With Brain Cancer,Ependymoma; Medulloblastoma; Glioblastoma; Primary Brain Tumor,Phase 1,Treatment
DCTPepD0091,NCT01042535,A Phase 1/2 Study of Ad.p53 DC Vaccine in Combination With 1-methyl-D-tryptophan in Metastatic Solid Tumors and Invasive Breast Cancer,"Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific",Phase 1/2,Treatment
DCTPepD0092,NCT04341311,Phase 1 Trial of Marizomib Alone and in Combination With Panobinostat for Children With Diffuse Intrinsic Pontine Glioma,"Diffuse Intrinsic Pontine Glioma; Pediatric Brainstem Glioma; Pediatric Brainstem Gliosarcoma, Recurrent; Pediatric Cancer; Pediatric Brain Tumor; Diffuse Glioma",Phase 1,Treatment
DCTPepD0092,NCT02103335,"A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma",Multiple Myeloma in Relapse; Refractory Multiple Myeloma; Multiple Myeloma,Phase 1,Treatment
DCTPepD0092,NCT00667082,"NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma",Non-Small Cell Lung Cancer; Pancreatic Cancer; Melanoma; Lymphoma; Multiple Myeloma,Phase 1,Treatment
DCTPepD0092,NCT00629473,A Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies,Advanced Cancer,Phase 1,Treatment
DCTPepD0092,NCT03345095,A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma,Newly Diagnosed Glioblastoma,Phase 3,Treatment
DCTPepD0093,NCT01299636,"Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors",Solid Tumors,Phase 1,Treatment
DCTPepD0093,NCT03427268,"A Phase II, Open-label, Multicentre Study of PM060184 in Patients With Advanced Colorectal Cancer After Standard Treatment.",Advanced Colorectal Cancer,Phase 2,Treatment
DCTPepD0093,NCT02533674,"Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors",Solid Tumors,Phase 1,Other
DCTPepD0094,NCT00683085,Phase I/II Trial of Human Leukocyte Antigen (HLA)-A*02:01-restricted Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)-Derived Peptide Vaccination Combined With Conventional Dose of Gemcitabine for Advanced Pancreatic Cancer,Pancreatic Cancer; Pancreas Neoplasms,Phase 1/2,Treatment
DCTPepD0095,NCT00005949,"Phase II Study of Melanoma Vaccine (NSC #683472/675756, IND #6123) and Low-Dose, Subcutaneous Interleukin-2 in Advanced Melanoma",Recurrent Melanoma; Stage IV Melanoma,Phase 2,Treatment
DCTPepD0095,NCT00020475,Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma,Extraocular Extension MelanomaRecurrent Intraocular Melanoma,Phase 2,Treatment
DCTPepD0095,NCT00001705,Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence,Melanoma; Neoplasm Metastasis,Phase 2,Treatment
DCTPepD0096,NCT00433745,Wilm's Tumor 1 (WT1) Peptide Vaccination for Patients With High Risk Hematological Malignancies,Myelodysplastic Syndrome; Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML),Phase 2,Treatment
DCTPepD0096,NCT00488592,Efficacy of Peptide (WT1) and Peptide(PRI) Vaccination for Patients With Low Risk Myeloid Malignancies,Myelodysplastic Syndrome (MDS); Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML),Phase 2,Treatment
DCTPepD0097,NCT00488592,Efficacy of Peptide (WT1) and Peptide(PRI) Vaccination for Patients With Low Risk Myeloid Malignancies,Myelodysplastic Syndrome (MDS); Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML),Phase 2,Treatment
DCTPepD0097,NCT00004918,A Phase I/II Study of PR1 (NSC 698102) Human Leukemia Peptide Vaccine With Montanide ISA 51 (NSC 675756) or Montanide ISA 51 VG (NSC 737063) Adjuvant,Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Myeloid Leukemia in Remission; Chronic Phase Chronic Myelogenous Leukemia; Previously Treated Myelodysplastic Syndromes; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Relapsing Chronic Myelogenous Leukemia,Phase 1/2,Treatment
DCTPepD0098,NCT00194714,Phase I/II Study of Combination Immunotherapy for the Generation of HER-2/Neu (HER2) Specific Cytotoxic T Cells (CTL) in Vivo,HER2/Neu Positive; HLA-A2 Positive Cells Present; Stage IV Breast Cancer; Stage IV Ovarian Cancer,Phase 1/2,Treatment
DCTPepD0098,NCT00068614,A Phase I Trial Evaluating The Safety Of Intramuscular Injections Of HER-2 Protein AUTOVAC (PX104.1.6) In Patients With Breast Cancer,Breast Cancer,Phase 1,Treatment
DCTPepD0098,NCT00005023,A Phase I Vaccine Trial of a HER-2/Neu Peptide Incorporated Into PLG Microspheres in Patients With Advanced Stage HER2-Expressing Cancers,Breast Cancer; Lung Cancer; Ovarian Cancer,Phase 1,Treatment
DCTPepD0099,NCT04114825,"A Phase 2, Double-Blind, Placebo Controlled Study of RV001V in Men With Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer (BRaVac)",Prostate Cancer Recurrent,Phase 2,Treatment
DCTPepD0099,NCT03199872,"A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours",Prostate Cancer,Phase 1/2,Treatment
DCTPepD0100,NCT00470574,Pilot Study of Immunization of High Risk Breast Cancer Patients With a Sialyl Lewisª -Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant QS-21,Breast Cancer,Not Applicable,Treatment
DCTPepD0100,NCT00036933,Vaccination Of Prostate Cancer Patients With A Bivalent Vaccine Containing MUC-2 Glycopeptide And Globo H Conjugates Plus The Immunological Adjuvant QS21,Prostate Cancer,Phase 1,Treatment
DCTPepD0100,NCT00004249,Immunization Using Polysialic Acid-KLH or N-Propionylated Polysialic Acid-KLH Conjugate Plus the Immunological Adjuvant QS-21 in Patients With Small Cell Lung Cancer Who Have Achieved a Major Response to Initial Therapy,Lung Cancer,Phase 2,Treatment
DCTPepD0100,NCT00004156,Vaccination of High Risk Breast Cancer Patients With MUC-1 (Glycosylated) Keyhole Limpet Hemocyanin Conjugates Plus the Immunological Adjuvant QS21,Breast Cancer,Phase 1,Treatment
DCTPepD0100,NCT05638698,Phase II Randomized Trial Combining Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer(TESLA),Pancreas Cancer,Phase 2,Treatment
DCTPepD0101,NCT00939809,"A Phase II Evaluation of a Urokinase-Derived Peptide (A6) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma",Fallopian Tube Carcinoma; Malignant Ovarian Mixed Epithelial Tumor; Ovarian Brenner Tumor; Ovarian Clear Cell Cystadenocarcinoma; Ovarian Endometrioid Adenocarcinoma; Ovarian Mucinous Cystadenocarcinoma; Ovarian Serous Cystadenocarcinoma; Primary Peritoneal Carcinoma; Recurrent Ovarian Carcinoma; Undifferentiated Ovarian Carcinoma,Phase 2,Treatment
DCTPepD0102,NCT02019524,Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients,Breast Cancer; Ovarian Cancer,Phase 1,Treatment
DCTPepD0102,NCT01580696,Phase I/IIa Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients,Ovarian Cancer; Endometrial Cancer; Fallopian Cancer; Peritoneal Cancer,Phase 1/2,Treatment
DCTPepD0103,NCT02019524,Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients,Breast Cancer; Ovarian Cancer,Phase 1,Treatment
DCTPepD0103,NCT01580696,Phase I/IIa Trial of Folate Binding Protein (FBP) Peptide (E39) Vaccine in Ovarian and Endometrial Cancer Patients,Ovarian Cancer; Endometrial Cancer; Fallopian Cancer; Peritoneal Cancer,Phase 1/2,Treatment
DCTPepD0104,NCT00066729,"A Phase I Study Of NY-ESO-1b Peptide Plus Montanide ® ISA-51 In Patients With Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer",Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer,Phase 1,Treatment
DCTPepD0104,NCT00199836,A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer Expressing NY-ESO-1 or LAGE-1.,Cancer; Neoplasm,Phase 1,Treatment
DCTPepD0105,NCT00068211,A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Inoperable Locally Advanced or Metastatic Melanoma.,Melanoma,Phase 2,Treatment
DCTPepD0105,NCT00082134,A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Every 21 Days in Patients With Hormone-Refractory Prostate Cancer Previously Treated With Docetaxel,Hormone-refractory Prostate Cancer,Phase 2,Treatment
DCTPepD0105,NCT00078455,A Phase II Study of ILX651 Administered Intravenously Daily for Five Consecutive Days Once Every 3 Weeks in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Phase 2,Treatment
DCTPepD0106,NCT00911443,"A Phase II, Multicentre, Open, Randomised, Dose Ranging Study to Investigate the Efficacy of Combination Therapy Containing Dacarbazine (DTIC) Plus Low Dose Interferon Alpha (aIFN) Plus Thymosin a1 Versus Both DTIC Plus Thymosin a1 and DTIC Plus aIFN in Patients With Advanced -Stage Metastatic Malignant Melanoma",Malignant Melanoma,Phase 2,Treatment
DCTPepD0106,NCT00082082,A Trial of Thymalfasin With Trans Arterial Chemo-Embolization (TACE) in the Treatment of Adult Patients With Unresectable Hepatocellular Carcinoma: A Phase II Trial,"Carcinoma, Hepatocellular",Phase 2,Treatment
DCTPepD0106,NCT02787447,A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy,Lung Adenocarcinoma,Phase 2,Treatment
DCTPepD0106,NCT02545751,"A Phase II Study of Stereotactic Body Radiation Therapy and ZADAXIN's® (Thymalfasin) Induced Tumor Effects in Patients With Heavily Pretreated, Metastatic Esophageal Cancer",Esophageal Cancer; Metastatic Esophageal Cancer; Stereotactic Body Radiation Therapy; Thymalfasin,Phase 2,Treatment
DCTPepD0106,NCT05086614,The Efficacy and Safety of Thymosin-alpha 1 Used for Adjuvant Treatment After Radical Resection of High-risk Stage II and Stage III Colorectal Cancer,Stage II/III Colorectal Cancer,Phase 3,Treatment
DCTPepD0107,NCT02924272,"An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies",Multiple Myeloma; Lymphoma; Amyloidosis,Phase 2,Treatment
DCTPepD0107,NCT03616782,Multicenter Phase II Study of Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma,Mantle Cell Lymphoma,Phase 2,Treatment
DCTPepD0107,NCT02302846,Phase II Study Of Ixazomib As Maintenance Therapy For Patients With Acute Myeloid Leukemia (AML) And High Risk Myelodysplastic Syndrome (MDS) In Remission,Leukemia,Phase 2,Treatment
DCTPepD0107,NCT02993094,Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer,Triple-Negative Breast Cancer,Phase 1/2,Treatment
DCTPepD0107,NCT02181413,"A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant",Multiple Myeloma; Autologous Stem Cell Transplant,Phase 3,Treatment
DCTPepD0108,NCT04534322,An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma,Relapsed and/or Refractory Multiple Myeloma,Expanded Access Program (Approved for marketing),Treatment
DCTPepD0108,NCT03151811,"A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide",Multiple Myeloma,Phase 3,Treatment
DCTPepD0108,NCT03481556,An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma,Multiple Myeloma,Phase 1/2,Treatment
DCTPepD0108,NCT03639610,A Study of the Pharmacokinetics of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma and Impaired Renal Function,Renal Impairment; Multiple Myeloma,Phase 2,Treatment
DCTPepD0108,NCT04649060,"A Randomized, Controlled, Open-Label Phase 3 Study of Melflufen in Combination With Daratumumab Compared With Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma",Relapsed Multiple Myeloma; Relapsed-Refractory Multiple Myeloma,Phase 3,Treatment
